FIG 1.

Flowchart of patient selection. KRAS, NRAS, and BRAF mutation status was determined on tumor tissue for a total of 419 patients with CRC with isolated and initially unresectable liver metastases enrolled in the CAIRO5 clinical trial. Patients without a KRAS-mutated tumor were excluded from the current study. Next, patients not treated with bevacizumab and chemotherapy were excluded to ensure a homogenous patient group. Last, patients without clinical follow-up were excluded, resulting in 156 patients with mCRC for analyses. CRC, colorectal cancer; ctDNA, circulating tumor DNA; CT, computed tomography; mCRC; metastatic colorectal cancer.